Neoleukin Therapeutics, Inc. announced resignation of Robert Ho as Chief Financial Officer to pursue another opportunity, effective March 1, 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
31.69 USD | -1.31% | -3.84% | +61.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+61.35% | 413M | |
+53.02% | 63.85B | |
-2.35% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.45% | 26.52B | |
-21.50% | 18.69B | |
+2.71% | 12.73B | |
+22.24% | 12.11B | |
+27.75% | 12.07B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neoleukin Therapeutics, Inc. Announces Resignation of Robert Ho as Chief Financial Officer, Effective March 1, 2022